Pneumonia Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00 – $ 8,900.00

Pneumonia Therapeutics Market: By Therapeutics (Prevention Vaccines and Treatment Drugs), Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), Age Group (Pediatric, Adult, and Geriatric), And Region (North America, Europe, Asia Pacific, Latin America, And MEA) And Forecast To 2028

Request Sample

Request Methodology

Request Sample

$ PRICE - $ 3,000.00 – $ 8,900.00

Clear selection

SKU: N/A Category: Healthcare

Description
Table Of Content
Company Profile

Report

Description

Pneumonia Therapeutics Market size was valued at USD 14,956.4 million in 2022 and is expected to grow at a CAGR of 8.7% from 2023-2029. Pneumonia is an inflammatory medical disorder that disturbs the alveoli and air sacs in the lungs. Pathogens such as viruses, bacteria, and fungi are the leading cause of pneumococcal infection using inhalation of air-borne droplets from coughing or sneezing. Pneumonia can also happen through contact with surfaces and objects that are soiled with pneumonia-causing viruses and bacteria. According to the kind of case, the medicines are to be given. For example, if pneumonia is produced by bacteria, an antibiotic is prescribed. Pneumonia therapeutics comprise the approaches such as drugs and vaccinations that can support managing of the infection. The infection can be severe but are predominantly lethal to children, infants, and individuals over 65. The rising prevalence of pneumococcal disease can lead to the growth of the pneumonia therapeutics market. Moreover, the growing pollution level in the environment, the introduction of preventive vaccination programs, and improved standards introduced by healthcare facilities over the market are some primary factors that can boost the global pneumonia therapeutics market share. Apart from these, the increased prevalence rate of lung illnesses worldwide can also accelerate the market in the future. However, some factors, such as the absence of patient awareness and restricted access to therapy, may restrain the growth of the market. The current clinical trials for the expansion of vaccine and drug molecules can create an opportunity for the growth of the global pneumonia therapeutics market.

Recent Market Developments:

In October 2022, BioLink received funds to develop a Covid-19 pneumonia treatment.

In August 2022, Pfizer announced positive top-line results from the Phase 3 Study of the 20-valent pneumococcal conjugate vaccine in infants.

Pneumonia Therapeutics Market

MARKET SUMMARY

8.7%

Study Period– 2022 – 2028
Base Year– 2021
CAGR– 8.7%
Largest Market– Asia Pacific
Fastest Growing Market– North America

Pneumonia Therapeutics Market

The global pneumonia therapeutics market report gives comprehensive outlook on bovine respiratory disease treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
The pneumonia therapeutics market report gives historical, current, and future market sizes (US$ Mn) on the basis of therapeutics, distribution channel, age group, and region.

Key Players

Allergan
AstraZeneca
Bayer
Cipla
GlaxoSmithKline Plc.

Pneumonia Therapeutics Market Dynamics

One of the major reasons for the growth of the global pneumonia therapeutics market is the growing funding for the development of the new product to report disease management. The high brutality of pneumonia, together with high demand from the market, is expected to propel the growth of the market in the forecast period. For example, in the current scenario, various companies working in the pneumonia therapeutics market, which comprises market giants like Merck, Pfizer, and GSK, are maneuvering huge capital and putting massive efforts into such research and development activities. This is further enhanced by positive clinical trials and regulatory approvals from concerned authorities.

North-America Got Significant Share

Pneumonia Therapeutics Market

North America is dominating the global pneumonia therapeutics market due to the growing geriatric population and growing multidrug resistance in children and adults, repeats the demand for the development of advanced-generation therapeutics. Moreover, global market players are capitalizing more on research and development and concentrating on new product development actions, which have also contributed to the growth of the market. However, numerous government initiatives intended for the treatment and prevention of pneumonia are accountable for generating a positive influence across North America.

Latin-America

North-America

Europe

Asia-Pacific

Middle East

Key

Key Features of the Report

The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
The report tracks recent innovations, key developments and startup’s details that are actively working in the market
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Pneumonia Therapeutics Market Segmentation

therapeutics

Prevention Vaccines
Treatment Drugs

Distribution Channel

Hospitals
Pharmaceutical Stores
Others

Age Group

Pediatric
Adult
Geriatric

Location

GEOGRAPHY

Frequently Asked Questions

The absence of patient awareness and restricted access to therapy can hinder the market growth.

The current clinical trials for the expansion of vaccine and drug molecules can create an opportunity for the growth of the global pneumonia therapeutics market.

In September 2022, FDA approved Nabriva Therapeutics’ Xenleta (lefamulin) to treat community-acquired bacterial pneumonia (CABP) as the first in a new class of antibiotics called pleuromutilins, which target a different protein synthesis binding site than older competitors.

Report

Table Of Content

1. Executive Summary

2. Global Pneumonia Therapeutics Market Introduction

2.1. Global Pneumonia Therapeutics Market – Taxonomy

2.2. Global Pneumonia Therapeutics Market –Definitions

2.2.1. Therapeutics

2.2.2. Distribution Channel

2.2.3. Age Group

2.2.4. By Region

3. Global Pneumonia Therapeutics Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Pneumonia Therapeutics Market Dynamic Factors – Impact Analysis

3.6. Global Pneumonia Therapeutics Market – Competition Landscape

4. Global Pneumonia Therapeutics Market, By Therapeutics, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

4.1. Prevention Vaccines

4.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

4.1.3. Market Opportunity Analysis

4.2. Treatment Drugs

4.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

4.2.3. Market Opportunity Analysis

5. Global Pneumonia Therapeutics Market, By Distribution Channel, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

5.1. Hospitals

5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Pharmaceutical Stores

5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Others

5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

6. Global Pneumonia Therapeutics Market, By Age Group, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

6.1. Pediatric

6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Adult

6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Geriatric

6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

7. Global Pneumonia Therapeutics Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

7.1. North America

7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Europe

7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Asia-Pacific

7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Latin America

7.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

7.5. Middle East and Africa

7.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

7.6. Global Pneumonia Therapeutics Market – Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Region, 2022-2028

8. North America Pneumonia Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

8.1. Therapeutics Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

8.1.1. Prevention Vaccines

8.1.2. Treatment Drugs

8.2. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

8.2.1. Hospitals

8.2.2. Pharmaceutical Stores

8.2.3. Others

8.3. Age Group Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

8.3.1. Pediatric

8.3.2. Adult

8.3.3. Geriatric

8.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

8.4.1. USA

8.4.2. Canada

8.5. North America Pneumonia Therapeutics Market – Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2022-2028

8.6. North America Pneumonia Therapeutics Market Dynamics – Trends

9. Europe Pneumonia Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

9.1. Therapeutics Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1. Prevention Vaccines

9.1.2. Treatment Drugs

9.2. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.2.1. Hospitals

9.2.2. Pharmaceutical Stores

9.2.3. Others

9.3. Age Group Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.3.1. Pediatric

9.3.2. Adult

9.3.3. Geriatric

9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. Germany

9.4.2. UK

9.4.3. France

9.4.4. Spain

9.4.5. Italy

9.4.6. Rest of Europe

9.5. Europe Pneumonia Therapeutics Market – Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2022-2028

9.6. Europe Pneumonia Therapeutics Market Dynamics – Trends

10. Asia-Pacific Pneumonia Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

10.1. Therapeutics Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Prevention Vaccines

10.1.2. Treatment Drugs

10.2. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.2.1. Hospitals

10.2.2. Pharmaceutical Stores

10.2.3. Others

10.3. Age Group Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.3.1. Pediatric

10.3.2. Adult

10.3.3. Geriatric

10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. China

10.4.2. India

10.4.3. Japan

10.4.4. ASEAN

10.4.5. Australia & New Zealand

10.4.6. Rest of Asia-Pacific

10.5. Asia-Pacific Pneumonia Therapeutics Market – Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2022-2028

10.6. Asia-Pacific Pneumonia Therapeutics Market Dynamics – Trends

11. Latin America Pneumonia Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

11.1. Therapeutics Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Prevention Vaccines

11.1.2. Treatment Drugs

11.2. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.2.1. Hospitals

11.2.2. Pharmaceutical Stores

11.2.3. Others

11.3. Age Group Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.3.1. Pediatric

11.3.2. Adult

11.3.3. Geriatric

11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. Brazil

11.4.2. Mexico

11.4.3. Rest of Latin America

11.5. Latin America Pneumonia Therapeutics Market – Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2022-2028

11.6. Latin America Pneumonia Therapeutics Market Dynamics – Trends

12. Middle East and Africa Pneumonia Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)

12.1. Therapeutics Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Prevention Vaccines

12.1.2. Treatment Drugs

12.2. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.2.1. Hospitals

12.2.2. Pharmaceutical Stores

12.2.3. Others

12.3. Age Group Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.3.1. Pediatric

12.3.2. Adult

12.3.3. Geriatric

12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Gulf Cooperation Council (GCC) Countries

12.4.2. South Africa

12.4.3. Rest of MEA

12.5. MEA Pneumonia Therapeutics Market- Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2022-2028

12.6. MEA Pneumonia Therapeutics Market Dynamics – Trends

13. Competition Landscape

13.1. Strategic Dashboard of Top Market Players

13.2. Company Profiles (Introduction, Financial Analysis, Key Therapeuticss, Key Developments, Strategies, and SWOT Analysis)

13.2.1. Abbott Laboratories

13.2.2. Allergan

13.2.3. AstraZeneca

13.2.4. Bayer

13.2.5. Cipla

13.2.6. GlaxoSmithKline Plc.

13.2.7. Lupin Pharmaceuticals Ltd.

13.2.8. Merck

13.2.9. Mylan

13.2.10. Novartis AG

13.2.11. Pfizer, Inc.

14. Research Methodology

15. Key Assumptions and Acronyms

Description

Description

Recent Market Developments:

In October 2022, BioLink received funds to develop a Covid-19 pneumonia treatment.

In August 2022, Pfizer announced positive top-line results from the Phase 3 Study of the 20-valent pneumococcal conjugate vaccine in infants.

search

Pneumonia Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

Description

Pneumonia Therapeutics Market

Pneumonia Therapeutics Market

Key Features of the Report

therapeutics

Distribution Channel

Age Group

GEOGRAPHY

Frequently Asked Questions

Table Of Content

Company Profile

Description

Product categories

Our Clients

ASIA PACIFIC OFFICE

EUROPE OFFICE